

**Question for written answer E-005545/2020
to the Commission**
Rule 138
César Luena (S&D)

Subject: Establishing a high-level forum to implement the Pharmaceutical strategy for Europe

In order to meet the demands of the European Parliament and the Council and in response to the failures identified by the current pandemic, the Pharmaceutical strategy for Europe will examine issues such as inadequate access by patients to new medicines and their affordability, shortages of certain medicines and pharmaceuticals, Europe's dependence on non-EU countries, the risk to the sustainability of health systems, and the regulatory framework needed for innovation based on medical needs.

Nevertheless, this strategy is only the first step in a long process involving the implementation of future legislative and non-legislative measures that will affect patients, the pharmaceutical industry, insurers, payers, national experts, regulatory agencies and public health systems, among others.

In this context, the Commission launched a public consultation to gather feedback on the issue. In the Commission's view, will the implementation of the strategy not require a structured dialogue with the various stakeholders in order to ensure that there is an open debate?

1. How does the Commission intend to coordinate this dialogue?
2. Does the Commission intend to organise a permanent high-level forum for this purpose?